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Abstract
Compromised blood-spinal cord barrier (BSCB) is a factor in the outcome following traumatic spinal cord injury
(SCI). Vascular endothelial growth factor (VEGF) is a potent stimulator of angiogenesis and vascular permeability.
The role of VEGF in SCI is controversial. Relatively little is known about the spatial and temporal changes in the
BSCB permeability following administration of VEGF in experimental SCI. Dynamic contrast-enhanced magnetic
resonance imaging (DCE-MRI) studies were performed to noninvasively follow spatial and temporal changes in
the BSCB permeability following acute administration of VEGF in experimental SCI over a post-injury period of
56 days. The DCE-MRI data was analyzed using a two-compartment pharmacokinetic model. Animals were
assessed for open field locomotion using the Basso-Beattie-Bresnahan score. These studies demonstrate that the
BSCB permeability was greater at all time points in the VEGF-treated animals compared to saline controls, most
significantly in the epicenter region of injury. Although a significant temporal reduction in the BSCB permeability
was observed in the VEGF-treated animals, BSCB permeability remained elevated even during the chronic phase.
VEGF treatment resulted in earlier improvement in locomotor ability during the chronic phase of SCI. This study
suggests a beneficial role of acutely administered VEGF in hastening neurobehavioral recovery after SCI.
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Introduction
Followingmechanical trauma to spinal cord, a seriesof pathobiological events ensue, leading to the so-called
‘‘secondary injury.’’ It is generally thought that much of the
neurologic deficit in SCI is the result of secondary injury. It is
therefore not surprising that major therapeutic efforts have
been directed towards slowing down or reversing the pro-
gression of secondary events in SCI (Bradbury andMcMahon,
2006; Rossignol et al., 2007). Dynamic vascular changes are
thought to play an important role in the evolution of sec-
ondary injury in SCI (Shingu et al., 1989; Blight, 1991; Popo-
vich et al., 1996; Tator and Koyanagi, 1997; Mautes et al., 2000;
Bilgen et al., 2001; Westergren et al., 2001; Casella et al., 2002;
Loy et al., 2002; Narayana et al., 2004; Maikos and Shreiber,
2007). Among others, some of the specific vascular changes
include angiogenesis and disruption of the blood-spinal cord
barrier (BSCB).
Vascular endothelial growth factor (VEGF) has multiple
and diverse functions that include endothelial cell mitogen-
esis, endothelial cell survival via antiapoptotic effects, vaso-
dilatation, and increased vascular permeability (Sledge, 2002).
Recent studies also indicate that VEGF exerts direct neuro-
trophic effects ( Jin et al., 2000; Matsuzaki et al., 2001; Fac-
chiano et al., 2002; Svensson et al., 2002), plays a role in axonal
growth (Kawakami et al., 1996), and stimulates proliferation
of stem cells ( Jin et al., 2002; Zhu et al., 2003). Studies by
Bartholdi et al. (1997) and Skold et al. (2000) have demon-
strated that cells within the lesioned spinal cord area are ca-
pable of expressing VEGF. Krum et al. (2002) demonstrated
that VEGF infusion produced a remarkable localized neo-
vascularization, leading to a 100% increase in the index of
cerebral vascular proliferation at 3 days following VEGF de-
livery. Similarly, Harrigan et al. (2002) reported that intra-
ventricular infusion of VEGF resulted in an increase in
capillary permeability and vessel density in a dose-dependent
manner.
Investigations into the role of VEGF in experimental SCI
have produced conflicting results that are summarized in
Table 1. The detrimental effect of VEGF in SCI was reported
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by Benton and Whittemore (2003). In these studies, a single
dose of VEGF was injected into the injured cord in a rat
model of contusion SCI. Profound and acute changes in the
microvascular permeability were observed in gray matter
(GM). By 6 weeks post-SCI, a profound exacerbation of le-
sion volume was apparent. These authors concluded that
‘‘intraparenchymal application of VEGF may exacerbate SCI,
likely through the effect on vessel permeability’’ (Benton and
Whittemore, 2003). In contrast, at least two other studies have
observed beneficial effects of VEGF in SCI. In one study,
Facchiano et al. (2002) investigated the effect of short- and
long-term administration of VEGF to the injured cord in a rat
model of transection SCI. A significant reduction in the extent
of retrograde corticospinal tract (CST) axonal degeneration
was observed, and evidence of axonal regeneration was pres-
ent. The reduced degeneration and increased regeneration
of axons was more evident when short-term VEGF treatment
was combined with long-term treatment. These improve-
ments appear to be the result of increased angiogenic activity
and possible neurotrophic effect exerted by VEGF (Facchiano
et al., 2002). In a rat model of contusion SCI, Widenfalk et al.
(2003) administered a single injection of VEGF directly into
the cord on the day of injury. At 6 weeks post-injury, VEGF-
treated animals showed improved behavioral scores relative
to controls. Widenfalk et al. (2003) concluded that the bene-
ficial effect seen in VEGF-treated animals could be the result of
increased blood vessels, protection and repair of vasculature,
decreased apoptosis, and possible protective effects on other
cells (Widenfalk et al., 2003).
As pointed out earlier, VEGF has an important effect on
BSCB permeability. It has been postulated that VEGF exac-
erbates injury by increasing the BSCB permeability and pro-
moting edema (Vaquero et al., 1999; Benton and Whittemore,
2003). However, relatively little is known about spatial and
temporal evolution of the BSCB permeability following the
administration of VEGF in SCI. Such an understanding is
critical for evaluating the role of VEGF in SCI.
Traditionally, the BSCB permeability has been assessed
ex vivo, using histological techniques. While such studies
provide a wealth of information about the BSCB permeability
at very high spatial resolution, histological approaches pro-
vide only static ‘‘snap shots’’ of the state of the BSCB perme-
ability and require large numbers of animals for statistically
reliable results. Therefore, noninvasive in vivo techniques for
evaluating the BSCB permeability are highly desirable. Such
techniques allow both spatial and temporal changes in the
BSCB permeability to be tracked in the same group of animals.
This methodology requires fewer animals and, more impor-
tantly, is clinically relevant.
Dynamic contrast-enhanced magnetic resonance imag-
ing (DCE-MRI) is a powerful noninvasive technique for
gaining valuable information about the BSCB permeability in
SCI (Runge et al., 1997; Bilgen et al., 2001; Bilgen and Nar-
ayana, 2001). DCE-MRI involves repeated acquisition of T1-
weightedMR images following intravenous administration of
paramagnetic contrast agents such as gadopentate dimeglu-
mine (Gd-DTPA, or Gd, for short) (Tofts et al., 1999). Nor-
mally, the BSCB is impermeable to largemolecules such as Gd
(molecular weight of 938 Da). However, when the BSCB is
compromised, Gd leaks out of the systemic vasculature into
the spinal cord, rendering these areas hyperintense on T1-
weightedMRI scans. In SCI, one generally observes two types
of enhancements on MRI: (1) diffuse enhancements (DE) that
are mainly the result of mechanical disruption of the vascu-
lature and are confined to the epicenter of injury and (2) focal
enhancements (FE) that are thought to represent neovascu-
lature and are generally seen away from the SCI epicenter
(Bilgen et al., 2001). In addition, areas that appear normal on
post-contrast T1-weighted images, termed non-enhancing
(NE), but with somewhat compromised BSCB, are also ob-
served (Cohen et al., 2009). Using an appropriate pharmaco-
kinetic model (Bilgen and Narayana, 2001), the temporal
changes in the contrast agent-induced signal increase can be
quantitatively related to the BSCB permeability (Bilgen et al.,
Table 1. Summary of in vivo Rodent Studies Investigating the Role of VEGF in SCI
Authors Source of VEGF VEGF’s effect in SCI Suggested mechanism
Vaquero et al., 1999 Endogenous (detected via
monoclonal antibody)
Negative Edema
Facchiano et al., 2002 Exogenous (human recombinant
VEGF or adenovirus
coding for VEGF)
Positive Angiogenic and neurotrophic
effects
Widenfalk et al., 2003 Exogenous (human
recombinant VEGF)
Positive Protection=repair of blood
vessels and decreased
apoptosis
Benton and Whittemore,
2003
Exogenous (human
recombinant VEGF)
Negative Increased blood-spinal
cord barrier permeability
Xiaowei et al., 2006 Endogenous (upregulation
via post-injury hypoxia)
Positive Hypoxia tolerance and
vascularity of injured
spinal cord
Choi et al., 2007 Endogenous (hypoxia-inducible
VEGF plasmid)
Positive Decreased apoptosis
Sakanaka et al., 2007 Endogenous (upregulation
via intravenous injection of
dihydroginsenoside Rb1)
Positive Protects against ischemia
Kao et al., 2008 Endogenous (upregulation via
administration of umbilical
cord blood-derived CD34þ cells)
Positive Reversing SCI-induced spinal
cord infarction and apoptosis
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2001, 2002, 2007; Bilgen and Narayana, 2001; Cohen et al.,
2009).
In this study, we used DCE-MRI to investigate the effects of
acutely administered VEGF on the spatial and temporal
evolution of the BSCB permeability up to post-injury day 56.
In addition, the behavioral status of the animals was assessed
using the Basso-Beattie-Bresnahan (BBB) score (Basso et al.,
1995). Our studies show that the BSCB permeability is higher
in VEGF-treated animals relative to saline-treated controls at
all time points. These longitudinal studies also provide evi-
dence of reduced BSCB permeability with time. Our studies
also suggest that acute VEGF treatment may be beneficial in
hastening neurobehavioral recovery after SCI.
Methods
The protocol employed in these studies was approved by
the institutional Animal Welfare Committee. All animal pro-
cedures were performed according to the NIH Guide for the
Care and Use of Laboratory Animals.
Spinal cord injury
Male Sprague-Dawley rats (300–350 g) were anesthetized
with spontaneous inhalation of isoflurane (4%). They were
then intubated and maintained under anesthesia by mechani-
cal ventilation. The spinal cord at the level of T7 was exposed
by removing the T7 spinous process and the corresponding
laminae, and a moderately severe contusion injury was pro-
duced using an in-house designed computer-controlled injury
device that has been shown to produce consistent injuries
(Cohen et al., 2009; Narayana et al., 2004). Briefly, the injury
device was designed to produce contusive-type injury and is
based on a linear motor (P01-23x80; LinMot Inc., Zurich,
Switzerland) mounted on an x-y-z platform (Sherline Pro-
ducts Inc., Vista, CA). The tip of the injury bit measured
0.5mm0.5mm. The mechanical parameters were as follows:
impact speed of bit¼ 1.5m=sec; cord compression¼ 1.7mm;
duration of compression¼ 80ms. These mechanical parame-
ters were shown to produce a consistent and moderately se-
vere injury to the spinal cord (Narayana et al., 2004).As judged
by the BBB locomotor score, which, as a behavioral outcome
measure, is one of the best ways to validate the severity of
injury across different SCImodels (Stokes and Jakeman, 2002),
our device produces a moderately severe injury that is com-
parable to that produced by commonly used SCI devices
(Table 2).
A piece of Gelfoam (Pharmacia & Upjohn Company, Ka-
lamazoo, MI) soaked with saline (40mL of 0.9% saline; Hos-
pira Inc., Lake Forest, IL) or VEGF (4 mg; R&D Systems,
Minneapolis, MN; diluted in 40mL of 0.1% bovine serum al-
bumin [BSA] in phosphate-buffered saline [PBS]), was placed
on the contusion site immediately after SCI. The VEGF dose of
4mg was selected based on previous results from Widenfalk
et al. (2003), who studied doses of 1 mg (low-dose), 4mg, and
20mg (high-dose) of VEGF in a rodent model of SCI. They
found that 4mg led to better outcomes than 1 mg, and that
20mg did not show significantly improved outcome com-
pared to 4mg.
For improved signal-to-noise ratio (SNR) in MRI, a RF coil
was implanted subcutaneously over the injury site without
touching the spinal cord (Fenyes and Narayana, 1998). The
woundwas closed in two layers. These serial studies required
repeated administration of contrast agent on different days.
For intravenous delivery of Gd (Magnevist; Berlex Labora-
tories, Montville, NJ) during the DCE-MRI scans, the right
jugular vein was cannulated, and a vascular port with silicone
tubing (Instech Solomon, Plymouth Meeting, PA) was im-
planted, and the incisions were closed. To ensure patency of
the jugular port and connected tubing over the 8-week du-
ration of the serial studies, 0.2mL of 0.9% saline was injected
into the port before and after each scan. If resistance on the
plunger of the syringe was felt during administration of the
saline bolus, the port or tubing was assumed to be blocked
and the animal was excluded from further MRI scanning.
Final confirmation of patency of the jugular port was assessed
after the DCE-MRI scan, in which contrast agent could be
readily observed in the vasculature.
Animal care
Animals were allowed to recover in warmed cages, and
saline was administered subcutaneously. Animals also re-
ceived Baytril-100 (2.5mg=kg; Bayer Healthcare LLC Animal
Division, Shawnee Mission, KS) and Buprenex (0.01mg=kg;
Table 2. A Comparison of BBB Scores Across Studies using Different SCI Contusion Devices in Rats.
Data is Presented as Mean Standard Deviation
Study
SCI contusion
level Injury device Injury severity
Control
‘‘treatment’’
Day 28 BBB
score
Day 42 BBB
score
Day 56 BBB
score
Current study T7 In-house
impactor
Moderately
severe
Saline 12.4 1.5 14.2 2.4 16.7 2.4
Jakeman et al.,
1998
T8 OSU ESCID1 0.9mm cord
displacement
Vehicle (PBS) 17.0 2.4 18.2 1.52 –
Ankeny et al.,
2001
T8 OSU ESCID1 1.0mm cord
displacement
Vehicle (PBS) 10.9 1.0 11.2 0.5 12.5 2.3
Widenfalk et al.,
2003
T9 NYU3 impactor 25mm WD
height
Ringer
solution
10.4 2.2 10.3 2.8 –
Cao et al., 2005 T9 IH4 impactor 150 kdyn None 13.5 2.0 – –
Mills et al., 2001 T10 NYU3 impactor 12.5mm WD
height
None 16.3 2.7 – –
Scheff et al., 2003 T10 IH4 impactor 150 kdyn None 13.6 2.8 13.5 1.8 –
1Ohio State University electromagnetic SCI device, 2day 43 BBB score, 3New York University, 4Infinite Horizon.
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Hospira Inc., Lake Forest, IL) subcutaneously. Animals’
bladders were manually expressed every 12 h until the return
of spontaneous urination.
Behavioral assessment
Prior to MRI scans, open-field BBB locomotor assessments
(Basso et al., 1995) were performed by two independent ob-
servers whowere blinded to the treatment, and BBB scores are
reported as the average of their two scores.
Magnetic resonance imaging protocol
The same group of animals underwent the DCE-MRI scans
on days 3, 7, 14, 28, 42, and 56 post-SCI. All MR studies were
performed on a 7-Tesla Bruker scanner (70=30 USR; Bruker
Biospec, Karlsruhe, Germany) using a 116-mm shielded gra-
dient insert that is capable of producing maximum gradient
amplitude of 400mT=m with 80-ms rise time. Animals were
placed in the supine position on a Plexiglas bed, and a
35mm40mm coil that was inductively coupled to the im-
planted RF coil was placed under the rat. On the day of MRI
scan, animals were anesthetized with an induction dose of 4%
isoflurane, and were then intubated and mechanically venti-
lated with 2–2.5% isoflurane, 30% oxygen, and 67.5–68% air
through a rodent ventilator (model 683; Harvard Apparatus,
Holliston, MA) for the duration of the scan (approximately
3 h). Silicone tubing (Instech Solomon) was attached to the
jugular portwith the other end of the tubing attached to a two-
way valve. Each of the two ports of the valvewas connected to
a syringe, one filled with Gd (Magnevist; Berlex Laboratories,
Montville, NJ) at a concentration of 287mg=kg and the other
with 0.9% saline. Prior to performing eachMRI scan, a quality
assurance scan that included SNR and magnetic field homo-
geneity assessment was performed, as described previously
(Cohen et al., 2009).
The respiratory rate and rectal temperature were moni-
tored throughout the experiment with a physiologic moni-
toring unit (model 1025; SA Instruments, Inc., Stonybrook,
NY). A pulse oximeter (model 8600V; Nonin Medical Inc.,
Plymouth, MN) was used to monitor heart rate and oxygen
saturation levels. For the duration of the experiment, a heating
system (model 11007B, SA Instruments, Inc.) was used to
maintain the body temperature at 378C. Following the ac-
quisition of a tri-pilot scan (for locating the spinal cord) and
high-resolution anatomical images, pre-contrast T1-weighted
spin echo, axial images were acquired (acquisition parame-
ters: repetition time [TR]¼ 500ms, echo time [TE]¼ 10.4ms,
field-of-view [FOV]¼ 2.6 cm2.6 cm, slice thickness¼ 1mm,
and acquisition matrix¼ 256128 [zero-filled to 256256]).
Then, without moving the animal, a 0.2-mL bolus of Gd was
injected in less than 5 sec into the jugular vein via the vascular
port. Immediately following the administration of Gd, T1-
weighted imageswere continuously acquired at 30 timepoints
with a temporal resolution of 2min, as part of the DCE-MRI
scan.
Mathematical model of Gd distribution
in the rat spinal cord
The model for analyzing the DCE-MRI data in rat spinal
cord was described previously (Bilgen and Narayana, 2001).
For quantification of Gd leakage through the compromised
BSCB, a two-compartment model was employed. One com-
partment represents the systemic circulation (intravascular)
and the second compartment represents the extravascular
extracellular space (EES) within the spinal cord. The adequacy
of a two-compartment model in spinal cord has been dem-
onstrated in Bilgen et al. (2001, 2002) and Cohen et al. (2009).
The concentration of Gd in the spinal cord EES at each time
point t, [Gd(t)EES], was estimated according to the following
equation (Cohen et al., 2009):
[Gd(t)EES]¼Kps ·
0:4
0:6Ksp þ
0:16
0:04Ksp
 
eKsp
t

 0:4
0:6Ksp
 
e 0:6t 0:16
0:04Ksp
 
e 0:04t

The parameters Kps and Ksp represent the transfer rates of
Gd from systemic circulation to the EES and from the EES
back to systemic circulation, respectively. The rate of influx
of Gd from the systemic circulation into the EES is Kps ·
[GD(t)]Systemic Circulation and the rate of disappearance of Gd
from the EES is Ksp · [GD(t)]EES. The values of Gd(t)EES at each
time point (based on DCE-MRI data) were fitted to the above
equation using Matlab (MathWorks, Inc., Natick, MA) to es-
timate Kps and Ksp. Because of the uncertainty in the exact
time of Gd injection and because it improved the ability of the
model to fit the data, the time of contrast injection (t0) was also
estimated as a part of the curve fitting routine.
Tissue processing and histology
Immunohistochemistry (IHC) was performed to detect al-
bumin extravasation into the spinal cord parenchyma for
BSCB permeability assessment and to confirm the DCE-MRI
results. Previous studies have directly (Cohen et al., 2009;
Gordh et al., 2006; Maikos and Shreiber, 2007) or indirectly
(Sharma et al., 2006) assessed albumin extravasation as an
indicator of BSCB integrity in rodent models of spinal cord
injury.
Following the terminal MRI scans on day 56 post-SCI, four
saline control animals, four VEGF-treated animals, and one
uninjured animal were transcardially perfused with saline
followed by 4% paraformaldehyde (PFA) in PBS. The spinal
cordswere then removed, postfixed overnight in 4% PFA, and
immersed in 30% sucrose-PBS (0.1M PBS) for 2–3 days at 48C.
Spinal cords were sectioned into three segments of 3mm
length each: an epicenter segment (centered around the lesion
site), a rostral segment, and a caudal segment. Each segment
was embedded in tissue freezing medium and frozen at
208C. Spinal cord segments were sectioned at 35 mm using a
cryostat (CM1800; LeicaMicrosystems, Inc., Bannockburn, IL)
and stored at 208C in tissue storing media.
Spinal cord sections were immunofluorescently stained for
albumin as described previously (Cohen et al., 2009). Tissue
sections were viewed and captured using a Spot Flex digital
camera (Diagnostic Instruments, Inc., Sterling Heights, MI)
attached to a Leica RX1500 upright microscope (Leica Mi-
crosystems, Inc.). 10fluorescence imageswere capturedwith
SPOT Advanced imaging software (Diagnostic Instruments,
Inc.). For comparisons between sections, the exposure time
was held constant for a given magnification level. The pri-
mary antibody in one set of spinal cord sections (negative
control) was omitted to confirm that the observed signal in the
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other spinal cord sections that were exposed to the primary
antibody is from albumin.
Data analysis
Exclusion criteria. Data were excluded if the rat died
during the 56-day period as the result of an observable illness
(e.g., bloody urine, lack of appetite, or porphyrin rings around
eyes). However, if an otherwise healthy rat died after the
completion of the MRI scan, the corresponding data was not
excluded.
MRI region of interest (ROI) analysis. Data were sepa-
rately analyzed for FE, DE, and NE areas. As described earlier
by Cohen et al. (2009), the enhancing (FE and DE) areas were
identified in an unbiased manner using the statistical decision
mechanism that is based on histogram analysis as described
elsewhere (Bilgen et al., 2001). FE areas were identified as lo-
calized hyperintense regions on axial spinal cord slices whose
signal intensity was at least double that of the mean signal
intensity for the entire slice. DE areas were identified as hy-
perintense patches on post-contrast MR images of the spinal
cord. This was realized following the consensus between two
independent observers. If FE or DE areas were present in a
MRI slice, the NE area for that slice was determined by sub-
tracting the enhancing areas from the total spinal cord cross
section. If no FE or DE areaswere present, then theNE area for
that slice was the ROI of the entire spinal cord. Thus, it was
possible for a single slice of the spinal cord to simultaneously
contain NE, FE, and DE areas. Due to insufficient number of
DE areas (which are mainly confined to the epicenter region),
it was not possible to adequately analyze DE data or to
compare DE data with NE and FE data. Thus, results for DE
areas are not presented here. In addition, due to the appear-
ance of FE areas predominantly in the chronic period (after
day 14 post-SCI [Bilgen et al., 2001]), the results for Kps in the
FE areas during the acute and subacute periods were not in-
cluded in the analysis.
Estimation of Kps and Ksp. Even though both Kps and Ksp
were determined, we have focused mainly on Kps because this
is the parameter that represents leakage of Gd from the sys-
temic circulation and is a measure of the BSCB permeability.
Further, the estimation of Ksp tends to be noisy because it is
computed from the decaying part of the curve (Bilgen and
Narayana, 2001). Due to the longitudinal nature of our study,
we had six time points. In addition, three spatial regions were
under consideration. In order to provide meaningful interpre-
tations of spatio-temporal changes, the key focus of our studies,
in accordance with our strict adherence to Bonferroni correc-
tion, we collapsed the temporal data into three time periods:
acute (day 3 post-SCI), subacute (days 7–14 post-SCI), and
chronic (days 28–56 post-SCI). This is consistent with the time
periods used in our previously published study of longitudinal
data that used the same time points for data acquisition (Cohen
et al., 2009). Therefore, in addition to comparing the values of
Kps by individual days, data was also analyzed by these three
post-SCI time periods. For the same reasons, the spinal cord
locationswere grouped into three spatial regions: caudal (slices
that were 4–8mm caudal to the injury epicenter), epicenter
(slices that were 2mm away from the injury epicenter, in-
cluding the epicenter slice), and rostral (slices that were 4—
8mmrostral to the injury epicenter). For eachMRI scan, the SCI
epicenter was determined independently by two observers as
the slice with the largest lesion. If the observers’ choice of epi-
center slice did not match, the observers conferred until the
epicenter slice was agreed upon.
Statistical analysis
Statistical analyses were performed using STATA (Inter-
cooled Stata 9.2 for Windows; StataCorp LP, College Station,
TX). The longitudinal data were analyzed using generalized
estimating equations (GEEs) for assessment of longitudinal
temporal association between BBB scores and Kps. Testing for
the significance of the relationship between the BBB scores
and Kps was based on a population-averaged, panel-data
model (Zeger and Liang, 1986). Unlike multiple analysis of
variance (MANOVA), which requires the imputation of
missing data by using options such as last value carried for-
ward, longitudinal interpolation, and longitudinal regres-
sion, GEE can handle cases with missing data without the
need for imputation (Twisk and de Vente, 2002). Using vari-
ous imputation methods to run MANOVA and GEE on an
incomplete longitudinal dataset, Twisk and de Vente (2002)
concluded that not imputing missing data would result in
superior GEE results, while imputing missing data would
result in superior MANOVA results. Because no imputation
technique is without bias to the resulting complete dataset, we
chose to not impute any missing data and employed GEE
analysis.
All other statistical procedures used the Wilcoxon signed-
rank test. MANOVA analysis assumes intra-group normal
distribution. Wilcoxon signed-rank tests, like the F-test
(modified MANOVA), are more robust in the analysis of
experimental data that cannot be assumed to be normally
distributed. All values are reported as mean standard de-
viation unless otherwise stated. Statistical significance was
defined as p< 0.05, with corrections for multiple comparisons
(Bonferroni adjustment).
Results
Table 3 summarizes the number of animals that were
scanned at each time point for the saline and VEGF cohorts.
Non-enhancing areas
Figure 1a,b displays Kps values for both groups, averaged
over the three spatial regions, plotted by post-SCI time period.
For VEGF animals, Kps was significantly smaller (i.e., lower
BSCB permeability) in the chronic period compared to both
acute ( p< 0.0001) and subacute ( p< 0.001) periods (Wilcoxon
rank-sum test, corrected a¼ 0.0167). For saline animals, Kps
was significantly greater in the acute period compared to
both subacute ( p< 0.01) and chronic ( p< 0.0001) periods. In
general, the value of Kps is greater in the VEGF animals rel-
ative to saline controls, but this difference reached statistical
Table 3. Summary of Number of Animals in Each
Treatment Group on Each Post-SCI MRI Scan Day
Day 3 Day 7 Day 14 Day 28 Day 42 Day 56
Saline 5 6 6 5 5 5
VEGF 4 6 8 6 5 6
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significance only in the subacute period ( p< 0.01). Table 4
summarizes these results as well as results for the pair-wise
individual post-SCI day comparisons of Kps for each cohort.
Figure 2 shows the values of Kps at each spatial region of the
spinal cord, for the three post-SCI time periods. In the epi-
center region, Kpswas significantly greater in the VEGF cohort
compared to the saline cohort ( p< 0.01, two-tailed unpaired
Student t-test) during both the subacute and chronic periods.
Whereas Kps in the epicenter region during the subacute time
period contributed to the overall difference in Kps during this
time period (Figs. 1c and 2b), this was not the case during the
chronic time period (Figs. 1c and 2c). This could be due to
significant reduction in the Kps values between the subacute
and chronic phases in the VEGF cohort (Fig. 1b).
Focally enhancing areas
As mentioned earlier, FE areas on DCE-MRI represent
underlying angiogenesis, and these areas do not usually ap-
pear on DCE-MRI until after day 14 post-SCI (Bilgen and
Narayana, 2001). During the chronic period, the value of Kps
in the FE areas was 0.0254 0.0234min1 in VEGF-treated
animals and 0.0328 0.0209min1 in saline controls. These
values were not significantly different from each other ( p<
0.053, Wilcoxon rank-sum test, corrected a¼ 0.0167). Also
during the chronic period, we investigatedwhether the values
of Kps were different between the FE and NE areas, for each
cohort. During the chronic time period, only the saline cohort
exhibited a significant difference in Kps between the FE
(0.0328 0.0209min1) and NE (0.0174 0.0102min1) areas
( p< 0.0001, Wilcoxon rank-sum test, corrected a¼ 0.0167).
BBB scores
The significantly increased BBB score in the VEGF cohort
compared to the control cohort during the chronic phase
(Fig. 1d) is attributed to day 28 post-SCI, on which the BBB
score was significantly greater in the VEGF cohort (16 1.7)
compared to the saline cohort (12.4 1.5; p< 0.0077,Wilcoxon
rank-sum test, corrected a¼ 0.0083). While neurobehavioral
FIG. 1. Kps values and Basso-Beattie-Bresnahan (BBB) scores plotted over time, for both treatment groups. (a) Kps in non-
enhancing (NE) areas of saline controls. (b) Kps in NE areas of vascular endothelial growth factor (VEGF)–treated animals. (c)
Kps in NE areas of saline controls versus VEGF-treated animals. (d) BBB scores of saline controls versus VEGF-treated
animals. *p< 0.01, §p< 0.05, **p< 0.001, ***p< 0.0001. Error bars represent standard error of the mean.
Table 4. Summary of Statistically Significant Results for Pair-wise Time Period or Individual
Day Comparisons of Kps in Non-enhancing (NE) Areas, within Saline and VEGF Groups
Saline VEGF
Comparison for Kps p-value Significant? p-value Significant?
Time Period Comparisons acute vs. subacute p< 0.0026 Yesa p< 0.0808 Noa
acute vs. chronic p< 0.0001 Yesa p< 0.0001 Yesa
subacute vs. chronic p< 0.0239 Noa p< 0.0008 Yesa
Individual Day Comparisons day 3 vs. day 14 p< 0.0001 Yesb p< 0.003 Yesb
day 3 vs. day 28 p< 0.0001 Yesb p< 0.0001 Yesb
day 3 vs. day 42 p< 0.001 Yesb p< 0.0011 Yesb
day 3 vs. day 56 p< 0.0001 Yesb p< 0.0026 Yesb
day 7 vs. day 14 p< 0.019 Nob p< 0.0002 Yesb
day 7 vs. day 28 p< 0.0063 Nob p< 0.0001 Yesb
day 7 vs. day 42 p< 0.0787 Nob p< 0.0001 Yesb
day 7 vs. day 56 p< 0.001 Yesb p< 0.0001 Yesb
Corrected a for multiple comparisons¼ 0.0166a or 0.0033b.
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recovery was significantly accelerated in the VEGF cohort by
day 28 post-SCI, the BBB scores on day 56 post-SCI were not
significantly different between the saline (16.7 2.4) and
VEGF (16.9 1.7) cohorts ( p< 0.92).
Relationship between BBB scores
and the BSCB permeability
The BBB scores were correlated with Kps in the previously
defined areas (NE and FE), using the GEE procedure for a
population-averaged model (a corrected for multiple com-
parisons¼ 0.0167). For multiple correlations, the GEE proce-
dure matched Kps values by treatment group, time period,
and spatial region. Table 5 summarizes the results of statistical
significance testing for the associations between BBB scores,
and Kps values in the NE and FE areas. Figure 3 displays the
associations between NE area Kps values and the BBB scores,
for both cohorts.
The association between Kps and BBB scores was tested for
saline and VEGF cohorts separately. We first tested the as-
sociation irrespective of spatial region. In NE areas, only the
saline cohort showed a significant overall association
( p< 0.001) between Kps and BBB score, while in FE areas only
the VEGF cohort showed a significant overall association
( p< 0.016) between Kps and BBB score. Second, we tested the
association within each of the three previously defined re-
gions of the spinal cord, for each treatment. In NE areas, the
association between Kps and BBB score was statistically sig-
nificant in all three regions ( p< 0.001 in each region) for the
saline cohort, while statistical significancewas not achieved in
any individual region for the VEGF cohort. In FE areas, the
association between Kps and BBB score was statistically sig-
nificant in the caudal and rostral regions ( p< 0.001 in each
region) for the saline cohort while statistical significance was
not achieved in any individual region for the VEGF cohort.
Histological verification of DCE-MRI results
Histology was evaluated qualitatively. As shown in
Figure 4, albumin staining was prominent in the epicenter
region=segment, with more albumin extravasation seen in
the VEGF-treated animal compared to saline control. In the
caudal region=segment, albumin extravasation persisted, al-
though to a lesser extent and comparably between both
groups. The albumin staining in the uninjured control spinal
cord was similar to that observed for the negative control
sections that were not treatedwith the primary antibody (data
not shown).
Discussion
In these studies, we have investigated the spatio-temporal
changes in the BSCB permeability with DCE-MRI in a ro-
dent model of contusion SCI treated with VEGF. To the best
of our knowledge, this is the first study to longitudinally
track changes in the BSCB permeability in SCI with VEGF
treatment.
Effects of VEGF on locomotor recovery
The most important observation in the present studies is
the improved BBB scores on day 28 post-SCI in the VEGF-
treated animals relative to the saline controls. However, this
difference disappeared by day 56 post-SCI. Thus, VEGF ap-
pears to accelerate neurobehavioral recovery, but a persistent
improvement in BBB scores in VEGF-treated animals com-
pared to saline controls was not observed. This is somewhat
different from the observation byWidenfalk et al. (2003), who
reported significant improvements in the BBB scores on days
7, 35, and 42 post-SCI of rats treated with the same dose of
VEGF. This difference in neurobehavioral improvement ob-
served in our studies may be due to a number of factors;
Widenfalk et al. (2003) used a 25-g weight-drop (WD) at the
T9 level, while we used a moderately severe contusive injury
at the T7 level. Yet, the plateau effect on BBB scores observed
in our study was also present in the work of Widenfalk et al.
(2003), the difference being that the onset of plateau occurred
on day 28 post-SCI in our study and on day 14 post-SCI in
Widenfalk et al.’s study. The other difference in post-SCI
neurobehavioral improvement may be due to the method of
administration of treatment. Whereas Widenfalk et al.
FIG. 2. Changes in blood-spinal cord barrier (BSCB) per-
meability in non-enhancing (NE) areas over time, for both
groups. Kps in NE areas versus spatial region for both groups
during the acute (a), subacute (b), and chronic (c) time peri-
ods. *p< 0.01. Error bars represent standard error of themean.
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injected VEGF into the lesioned area of the spinal cord directly
after SCI, we placed a piece of Gelfoam soaked with VEGF on
top of the spinal cord directly after SCI. Longer duration
treatmentwith VEGF could possibly sustain the improvement
in the locomotor recovery.
Effects of VEGF on BSCB permeability
Three tissue areas of relevance were identified and studied
on DCE-MRI scans. While NE areas do not display visible
contrast enhancement and may appear normal upon visual
inspection, our quantitative analysis has demonstrated that
these areas of the spinal cord contain compromised BSCB. The
lack of visible enhancement in these areas suggests subtle
changes in the BSCB permeability of either the old vasculature
or neovasculature that is difficult to visualize on the post-
contrast T1-weighted images. Nevertheless, quantitative
analysis of the DCE-MRI studies suggests the presence of
compromised BSCB in the NE areas. However, the BSCB
permeability in these NE areas appears to significantly de-
crease with time in both cohorts, perhaps reflecting endoge-
nous recovery over time. While there is a trend of increased
NE area BSCB permeability in VEGF-treated animals com-
pared to saline controls, a significant treatment difference in
Kps, across all spatial regions, was only detected in the sub-
acute time period. The lack of a significant difference in Kps
between both cohorts during the other two time periods may
be due to (1) increased edema in NE areas observed on MRI
(Narayana et al., 1999) and increased hemorrhage (Bilgen
et al., 2000) in the acute phase, and (2) endogenous semi-
restoration of the BSCB in the chronic phase (Cohen et al.,
2009). Our spatio-temporal analysis also indicates significant
treatment differences in the NE areas only in the epicenter
region during the subacute (days 7–14 post-SCI) and chronic
(days 28–56 post-SCI) periods. The lack of a significant dif-
ference in NE area BSCB permeability at the injury epicenter
between the VEGF and saline cohorts possibly reflects in-
creased angiogenesis and increased permeability during the
early phases of angiogenesis (Dvorak et al., 1995, 1999).
Therefore, differences in NE area BSCB permeability during
the acute phase may be indistinguishable regardless of treat-
ment. For the chronic period, the results of BSCB permeability
as determined by DCE-MRI were verified through immuno-
histochemistry for albumin on spinal cords from animals
sacrificed at 56 days post-SCI. While VEGF-treated animals
demonstrated increased BSCB permeability compared to sa-
line controls in the epicenter region, albumin extravasation
was comparable between the two groups in the caudal region.
The values of Kps in FE areas were significantly larger
compared to the NE areas, but only in the subacute and
chronic time periods. The lack of a significant difference in the
BSCB permeability between FE andNE areas during the acute
period may be due to the relative absence of FE areas com-
pared to NE areas during this time period (Bilgen and Nar-
ayana, 2001).
Consistent with Vaquero et al.’s finding that endogenous
VEGF (measured via immunoreactivity in the arterioles of pia
mater and GM) decreased by day 14 post-SCI (Vaquero et al.,
1999), we have shown a statistically significant decrease in the
BSCB permeability from day 3 to day 14 post-SCI in saline
controls ( p< 0.0001; Table 4).
FIG. 3. Association between blood-spinal cord barrier
(BSCB) permeability and Basso-Beattie-Bresnahan (BBB)
scores. Kps of the non-enhancing (NE) areas are plotted over
time as closed squares. BBB locomotor scores are concurrently
plotted as open squares. Kps versus time and BBB score versus
time for saline (a) and vascular endothelial growth factor
(VEGF; b) cohort. **p< 0.001. Acute, subacute, and chronic
time periods represent 3 days, 7–14 days, and 28–56 days
post–spinal cord injury (SCI), respectively. Error bars repre-
sent standard error of the mean.
Table 5. Summary of Temporal Associations between BBB Scores and Kps Values
in the NE and FE Areas, for Both Cohorts
Tissue area Spatial region Saline cohort VEGF cohort Corrected a value
Non-enhancing (NE) all combined p< 0.001 (*) p< 0.078 0.05
caudal p< 0.001 (*) p< 0.144 0.0167
epicenter p< 0.001 (*) p< 0.083 0.0167
rostral p< 0.001 (*) p< 0.206 0.0167
Focal enhancements (FE) all combined p< 0.117 p< 0.016 (*) 0.05
caudal p< 0.001 (*) p< 0.628 0.0167
epicenter p< 0.309 p< 0.999 0.0167
rostral p< 0.001 (*) p< 0.047 0.0167
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Association between BSCB permeability
and locomotor recovery
Cohen et al. (2009) found a significant inverse correlation in
untreated injured animals between NE area Kps values and
BBB scores. In the current study, we found a similar signifi-
cant inverse temporal association in the control cohort. The
lack of a significant inverse correlation in the VEGF cohort
of the current study suggests that VEGF treatment does not
exacerbate the injury through the mechanism of compro-
mised BSCB permeability. This is consistent with the finding
of Benton and Whittemore (2003), of almost no significant
immunostaining differences in microvascular architecture
(blood vessel count, density, and diameter) at 6 weeks post-
SCI between VEGF and control cohorts. Interestingly, Benton
et al. observed a significant VEGF treatment effect on micro-
vasculature at 6 weeks post-SCI only in the ventral white
matter that is 2mm rostral to the SCI epicenter (Benton and
Whittemore, 2003). In our studies, during the chronic time
period, the only spatial region of the spinal cord that dem-
onstrated a significant difference in Kps between VEGF and
saline cohorts was the epicenter region, which contains slices
2mm rostral to the epicenter of injury. The absence of any
significant differences in lesion area between the saline and
VEGF cohorts at day 56 post-SCI in our study is somewhat
different from the findings of Benton et al., who reported a
significantly increased cavitation size of the spinal cord
6weeks post-SCI due to VEGF treatment, both at 2mm rostral
and 2mm caudal to the injury epicenter (Benton and Whit-
temore, 2003). Some of the differences between the results of
Benton et al. and those presented in our study may be due in
part to the timing of VEGF administration. While VEGF was
administered immediately after SCI in our study, Benton et al.
administered VEGF 3 days post-SCI (Benton andWhittemore,
2003).
We observed a significant correlation between BSCB per-
meability in the FE areas and BBB scores (1) in the VEGF
cohort when all three regions were considered together and
(2) in the saline cohort in the rostral and caudal regions. We
believe the lack of a significant correlation in the epicenter
region in both cohorts was due to the fact that most FE areas
were observed distal to the site of injury. In addition, the DE
areas that are due to mechanically damaged BSCB may have
overwhelmed the FE areas in the epicenter region, leading to a
diminution in the number of FE areas detected in this region.
Persistent increase in BSCB permeability over time
As previously reported by Cohen et al. (2009), the value of
Kps remained elevated during the chronic phase of the current
FIG. 4. Extravasation of albumin into the spinal cord parenchyma in the epicenter and caudal regions at 56 days post–spinal
cord injury (SCI). The increased albumin extravasation in the epicenter region in the vascular endothelial growth factor
(VEGF)–treated animal (b) compared to the saline control (a) can be seen. However, no significant difference in the albumin
extravasation was observed in the caudal region of the VEGF-treated animal (d) compared to the saline control (c). For
comparison, the uninjured spinal cord does not exhibit the extravasation of albumin (e). Three cords from each group were
qualitatively assessed and representative images are shown.
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study, even in regions away from the epicenter. This finding
in the context of chronically injured spinal cord could have
implications for longer-term interventions that employ small
therapeutic agents to penetrate the still compromised BSCB
(Baptiste and Fehlings, 2006).
Based on our studies, compromised BSCB permeability
does not appear to be the primary driving factor for VEGF’s
observed treatment effects in SCI. This finding might have
implications for combination therapies with particular em-
phasis on the effects of VEGF other than promoting vascular
permeability. The neuroprotective role of VEGF is thought to
be related to enhanced neurovascular perfusion that reduces
neurodegeneration (Oosthuyse et al., 2001; Storkebaum et al.,
2004). VEGF has also been shown to promote neurite out-
growth from cerebral cortical neurons ( Jin et al., 2006) and
retinal explants (Bocker-Meffert et al., 2002). Another option
for the use of VEGF in SCI is in combination with other an-
giogenic agents. For example, angiopoietin-1 has been shown
to stabilize adult vasculature (Thurston et al., 2000) and, in
combination with VEGF, has been show to stabilize neuro-
vasculature in a rodent model of stroke (Zacharek et al., 2007).
Thus, VEGF in combination with other therapies, with par-
ticular emphasis on timing of administration, may prove
beneficial in SCI.
Caveats
We have been using saline as a control in our previous
studies and simply continued that practice. BSA would have
been a better control. Rat albumin has previously been shown
to have a therapeutic effect in the context of experimental SCI
(Cain et al., 2007). However, the concentration of rat albumin
in Caine’s study was fivefold higher than the BSA vehicle
used in our VEGF cohort. While we cannot totally rule out the
effect of BSA vehicle (which was delivered via Gelfoam) on
BBB scores in the VEGF-treated group in our study, we be-
lieve that because of its low concentration, the BSA vehicle in
our study did not significantly confound the effects of VEGF
on BBB score.
While the number of animals used in this study (Table 3)
may be considered small and thus predispose the results of
BBB score comparisons to the potential for type II error, this
number of animals has been shown to be sufficient for com-
parisons of MRI metrics such as Kps (Cohen et al., 2009).
Conclusion
These studies demonstrate that the BSCB permeability was
greater at all time points in VEGF-treated animals compared
to saline controls, most significantly in the region containing
the SCI epicenter. Although a significant temporal reduction
in the BSCB permeability was observed in both saline and
VEGF cohorts ( p< 0.0001), BSCB permeability remained ele-
vated even during the chronic phase. Our studies indicate that
acutely administered VEGF hastens neurobehavioral recov-
ery by day 28 post-SCI but that this improvement over saline
controls does not persist by day 56 post-SCI. We have dem-
onstrated that NE areas on DCE-MRI scans represent areas of
compromised BSCB despite their normal-looking appearance.
These NE areas may play a significant role in the secondary
injury of SCI, and thereby functional outcome. Changes in the
BSCB permeability do not appear to be the primary driving
factors for VEGF’s observed treatment effects in SCI. This
finding might have implications for combination therapies
with particular emphasis on the effects of VEGF other than its
effect on promoting vascular permeability via angiogenesis
(e.g., neuroprotection via anti-apoptotic pathways, promo-
tion of neurite growth).
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